JP2021519261A - 細胞リプログラミングのための組成物および方法 - Google Patents

細胞リプログラミングのための組成物および方法 Download PDF

Info

Publication number
JP2021519261A
JP2021519261A JP2020551257A JP2020551257A JP2021519261A JP 2021519261 A JP2021519261 A JP 2021519261A JP 2020551257 A JP2020551257 A JP 2020551257A JP 2020551257 A JP2020551257 A JP 2020551257A JP 2021519261 A JP2021519261 A JP 2021519261A
Authority
JP
Japan
Prior art keywords
seq
mir
tlr3
nfκb
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551257A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019183415A5 (https=
JP2021519261A5 (https=
Inventor
コンラル ホジキンソン
コンラル ホジキンソン
ヴィクター ザウ
ヴィクター ザウ
ジェウ リ
ジェウ リ
ブルース エイ サレンジャー
ブルース エイ サレンジャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2021519261A publication Critical patent/JP2021519261A/ja
Publication of JPWO2019183415A5 publication Critical patent/JPWO2019183415A5/ja
Publication of JP2021519261A5 publication Critical patent/JP2021519261A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020551257A 2018-03-21 2019-03-21 細胞リプログラミングのための組成物および方法 Pending JP2021519261A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862645847P 2018-03-21 2018-03-21
US62/645,847 2018-03-21
US201862782480P 2018-12-20 2018-12-20
US62/782,480 2018-12-20
PCT/US2019/023461 WO2019183415A1 (en) 2018-03-21 2019-03-21 Compositions and methods for cellular reprogramming

Publications (3)

Publication Number Publication Date
JP2021519261A true JP2021519261A (ja) 2021-08-10
JPWO2019183415A5 JPWO2019183415A5 (https=) 2022-03-30
JP2021519261A5 JP2021519261A5 (https=) 2022-03-30

Family

ID=67988091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551257A Pending JP2021519261A (ja) 2018-03-21 2019-03-21 細胞リプログラミングのための組成物および方法

Country Status (5)

Country Link
US (1) US11512290B2 (https=)
EP (1) EP3768283A4 (https=)
JP (1) JP2021519261A (https=)
CA (1) CA3094658A1 (https=)
WO (1) WO2019183415A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024316608A1 (en) * 2023-08-02 2026-03-05 The Children's Medical Center Corporation Targeting tlr3 for treatment of hematopoietic stem cell proliferation-associated diseases or disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006577A2 (en) * 2010-07-08 2012-01-12 Duke University Direct reprogramming of cells to cardiac myocyte fate
WO2014169049A1 (en) * 2013-04-09 2014-10-16 Duke University 2' fluoro-modified rnas as immunostimulators
WO2016022992A1 (en) * 2014-08-07 2016-02-11 Duke University Compositions and methods for the reprogramming of cells into cardiomyocytes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109763A2 (en) * 2012-01-17 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University Activation of innate immunity for nuclear reprogramming of somatic cells
US10130637B2 (en) 2012-11-02 2018-11-20 Duke University Inhibition of histone methyltransferase for cardiac reprogramming
EP3270984A4 (en) * 2015-03-16 2019-04-17 Duncan Ross TREATMENT METHOD WITH MEMBRANE-INCLUDED VESICLE
CN110709515A (zh) * 2017-04-03 2020-01-17 杜克大学 用于差异性诱导细胞死亡和干扰素表达的组合物和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006577A2 (en) * 2010-07-08 2012-01-12 Duke University Direct reprogramming of cells to cardiac myocyte fate
WO2014169049A1 (en) * 2013-04-09 2014-10-16 Duke University 2' fluoro-modified rnas as immunostimulators
WO2016022992A1 (en) * 2014-08-07 2016-02-11 Duke University Compositions and methods for the reprogramming of cells into cardiomyocytes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CONRAD HODGKINSON ET AL., CIRCULATION, vol. Vol. 136, Suppl. 1, JPN6023014122, 14 November 2017 (2017-11-14), pages 16486, ISSN: 0005194460 *
JAEWOO LEE ET AL., MOLECULAR THERAPY, vol. 25, no. 6, JPN6023014121, June 2017 (2017-06-01), ISSN: 0005194462 *
TILANTHI M. JAYAWARDENA ET AL., CIRCULATION RESEARCH, vol. Vol. 110, Issue 11, JPN6023014123, 25 May 2012 (2012-05-25), ISSN: 0005194461 *

Also Published As

Publication number Publication date
EP3768283A1 (en) 2021-01-27
EP3768283A4 (en) 2022-03-30
US11512290B2 (en) 2022-11-29
CA3094658A1 (en) 2019-09-26
WO2019183415A1 (en) 2019-09-26
US20210017497A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
JP5898843B2 (ja) 血管新生、血管形成、若しくは血管修復を促進するか、又は腫瘍血管新生を阻害する方法
RU2656154C2 (ru) СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ
US20110152352A1 (en) Smad proteins control drosha-mediated mirna maturation
JP2015518714A (ja) 遺伝子発現を調節するための組成物及び方法
CN102239259A (zh) UsiRNA复合物
CA2921556A1 (en) Compositions and methods for modulating rna
CN104583406A (zh) 治疗kras相关疾病的有机组合物
US10612020B2 (en) Artificial mimic miRNA for controlling gene expression, and use of same
JP2013046616A (ja) ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
JP2013511964A (ja) ｍｉＲＮＡ−１００を含む医薬組成物ならびに血管増殖および内皮炎症を調節するためのその使用
US20240197640A1 (en) Systems and methods for exosome delivery of micrornas for cellular reprogramming
JPWO2011111824A1 (ja) マイクロｒｎａを用いた心筋細胞の増殖方法
JP5794559B2 (ja) 間葉系細胞の分化を調節するための薬剤及びその利用
WO2017152182A1 (en) Targeting microrna for cancer treatment
CN105586391B (zh) 人gtpbp4基因的用途及其相关药物
JP2021519261A (ja) 細胞リプログラミングのための組成物および方法
KR101541974B1 (ko) miR29b를 포함하는 신경줄기세포의 신경세포로의 분화 촉진용 조성물 및 방법
CN105779576A (zh) 人tnfrsf12a基因的用途及其相关药物
JP2025501269A (ja) アンチセンスオリゴヌクレオチド及びその使用
HK40016323A (en) Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease
BR112016000163B1 (pt) Estrutura de oligo rna de dupla hélice, nanopartículas, composição farmacêutica e formulação liofilizada
KR20130051520A (ko) Ｄｌｋ-1 유전자 발현억제용 조성물
HK1158680A (en) Usirna complexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231113